T-Vec
Phase 3 results announced for Imfinzi plus Imdelltra in extensive-stage small cell lung cancer
Around 195,000 people globally will be treated for this form of lung cancer in 2026
FDA approves Revolution Medicines’ first in class targeted therapy for metastatic pancreatic cancer
67,000 new cases of pancreatic cancer are diagnosed in the US each year
BriaCell advances personalised skin cancer immunotherapy vaccine candidate
Around 112,000 new cases of skin cancer will be diagnosed in the US in 2026
MSD and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
Cases of skin cancer set to reach 263,000 in 2035 according to new report
The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe
Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes
The treatment can be used to delay the onset of clinical type 1 diabetes
J&J’s Icotyde approved by US FDA for plaque psoriasis
Plaque psoriasis affects over 125 million people worldwide
Novo Nordisk’s Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes
The insulin is designed as an alternative to daily basal insulin
Johnson & Johnson’s multiple myeloma treatment approved by US FDA
The approval was based on phase 3 data showing survival rates of 83.3% after three years
Amgen agrees to lower prescription drug costs in deal with US government
The company has invested $40bn in US R&D and manufacturing in the past seven years
AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers
In 2022, nearly one million new patients were diagnosed with gastric cancer
Amgen reports positive results from landmark cardiovascular study
The study found significant reductions of major cardiovascular events in high-risk adults following treatment